News | August 02, 2024
GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr
Strong topline growth driven by solid performance across key brands.
Strong topline growth driven by solid performance across key brands.
Decision on EU marketing authorisation for this population expected by September 2024
GSK and Flagship to jointly fund up to $150 million upfront
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Subscribe To Our Newsletter & Stay Updated
